Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07224347 · ClinicalTrials.gov registry record

Aspirin in Reducing Events in the Elderly-Extension (ASPREE-XT)

A clinical trial of Depression and Cancer, sponsored by Anne Murray.

Active
Registry status
19,114
Enrollment target
20
Study locations

NCT07224347 is a study of Depression and Cancer that is active but no longer recruiting, run by Anne Murray. The registered enrollment target is 19,114 participants, above the 758-participant average among 679 other Depression trials with a reported enrollment target (2422% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07224347, a study of Depression and Cancer, is active but no longer recruiting, sponsored by Anne Murray.

ACTIVE NOT RECRUITING
Registry status
19,114 participants
Enrollment target
20
Study locations

Study Summary

ASPREE-XT is a post-treatment, longitudinal observational follow-up study of ASPREE participants. Although the ASPREE trial medication was ceased, the study activity was not stopped and ASPREE participants are continuing with scheduled visits and phone calls. An observational follow-up phase (ASPREE-XT), began in January, 2018. This will enable the monitoring of possible delayed effects of aspirin treatment, primarily on cancer incidence, metastases and mortality. In addition to monitoring the incidence of malignancy within the ASPREE cohort, the opportunity will be taken to observe any other residual effects of aspirin on the endpoints being monitored in the cohort. Continuity of contact with study participants is the key to retention of the cohort for any ongoing or future studies.

Conditions Studied

Depression Cancer Stroke Dementia Frailty Heart Disease Bleeding Functional Disability

Study Locations (20)

Georgia

  • Morehouse School of Medicine - Atlanta
  • Emory/ Atlanta VAMC - Atlanta

Louisiana

  • Pennington Biomedical Research Center - Baton Rouge
  • LSU Health Sciences- Shreveport - Shreveport

Michigan

  • University of Michigan - Ann Arbor
  • Wayne State University - Detroit

Minnesota

  • HealthPartners Research Institute - Minneapolis
  • Phalen Village Clinic - Saint Paul

North Carolina

  • Wake Forest University Baptist Medical Center - Greensboro
  • The Brody School of Medicine at East Carolina University - Greenville

Pennsylvania

  • Einstein Medical Center - Philadelphia
  • University of Pittsburgh Health Sciences Research Center - Pittsburgh

Texas

  • University of Texas Southwestern Medical Center at Dallas - Dallas
  • University of Texas Medical Branch - Galveston

Alabama

  • The University of Alabama at Birmingham - Birmingham

Trial Details

FieldValue
Enrollment Target 19,114 participants
Start Date 2019-07-15
Est. Completion 2026-04-30

Sponsor

Anne Murray

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07224347

The ClinicalTrials.gov registry entry for NCT07224347 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 19,114 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 758-participant average among 679 other Depression trials with a reported enrollment target (2422% higher). The listed sponsor is Anne Murray, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Depression appearing as the primary indexed condition, and to 0 interventions.

NCT07224347 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Georgia, Louisiana, Michigan.

Frequently Asked Questions

What is clinical trial NCT07224347 about?

NCT07224347 is a clinical study titled "Aspirin in Reducing Events in the Elderly-Extension (ASPREE-XT)". ASPREE-XT is a post-treatment, longitudinal observational follow-up study of ASPREE participants. Although the ASPREE trial medication was ceased, the study activity was not stopped and ASPREE participants are continuing with scheduled visits and phone calls. An observational follow-up phase (ASPREE...

What is the current status of trial NCT07224347?

This trial is currently active not recruiting. The enrollment target is 19,114 participants. The study started on 2019-07-15. Estimated completion is 2026-04-30.

What conditions does trial NCT07224347 study?

This clinical trial studies the following conditions: Depression, Cancer, Stroke, Dementia, Frailty.

Who is sponsoring clinical trial NCT07224347?

This trial is sponsored by Anne Murray, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07224347 being conducted?

This trial has 20 study locations across Alabama, District of Columbia, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Depression

All registered trials for this condition

Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.